|
|
|
|
PNP Therapeutics: BIRMINGHAM, Ala. - PNP Therapeutics Inc.
announced today the Food and Drug Administration has granted orphan drug status
to Gedeptin, the Company's lead product candidate (adenoviral vector expressing
E. coli purine nucleoside phosphorylase gene) for the intratumoral treatment of
anatomically accessible oral and pharyngeal cancers, including cancers of the
lip, tongue, gum, floor of mouth, salivary gland and other oral cavities.
"We are so pleased to have received the orphan drug
designation for Gedeptin, which could potentially improve the patient outcomes
of currently very difficult to treat diseases," said President of PNP
Therapeutics Jim Fuqua. "I am so proud of the outstanding work of the two
cofounders..
|
| Add to Outlook Calendar |
|
|
|
|
Memphis, TN—arGentis Pharmaceuticals, LLC announced today the issuance of EU patent No. 2,286,218 for a single nucleotide polymorphism (SNP) associated with resistance to immune tolerance. This SNP and will be used as a biomarker to identify patients that will respond to arGentis’ treatment for scleroderma.
For more information, contact:
Tom Davis, President and CEO, arGentis Pharmaceuticals, LLC
901-881-8665
|
| Add to Outlook Calendar |
|
|
|
http://finstonconsulting.com
|
Commercial Healthcare Partners is pleased to announce a collaboration with Finston Consulting based in Washington, D.C. Finston Consulting will provide data room collection and management services for CHP clients.
Finston Consulting is a Micro-Multinational, with services including strategic partnering, business development, trade and tariff advice, public affairs programs & capacity building in the areas of branding, social media, intellectual property (IP), tech transfer, genetic resources, and related environment issues, with special expertise in the BRICs and other emerging markets.
|
| Add to Outlook Calendar |
|
|
|
|
| SynAllergy seeks sales representatives and contract sales organizations to call on primary care physicians, pediatricians and other healthcare providers. Representatives receive a substantial commission and will be trained by SynAllergy. Successful candidates should a background in business to business sales. synAllergy offers primary care providers the ability to achieve better patient outcomes and a stronger financial future by helping them deliver with great ease, efficiency, and safety skin allergy testing and immunotherapy services.
|
| Add to Outlook Calendar |
|
|
|
|
WIXOM, Mich., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc.
(RMTI), a fully-integrated biopharmaceutical company targeting end-stage
renal disease (ESRD) and chronic kidney disease (CKD) with innovative
products and services for the treatment of iron replacement, secondary
hyperparathyroidism today announced that the Oncologic Drugs Advisory
Committee (ODAC) of the U.S. Food & Drug Administration (FDA)
recommended that the Phase 3 Triferic efficacy and safety results
support a positive benefit/risk to treat iron loss to maintain
hemoglobin in patients with hemodialysis-dependent stage 5 chronic
kidney disease (CKD). The ODAC voted in favor of Triferic by a vote of 8
to 3.
A complete dossier is available upon request. Please contact Commercial
Healthcare Partners for more information. Contact information below:
www.commercialhealthcarepartners.com
Phone 615-887-3847.
Jim Usry, Principal
|
| Add to Outlook Calendar |
|
|
|
|
|
What's happening NOW!
|
| Add to Outlook Calendar |
|
|
|
|
| CHP announces its affiliation with a Biopharm Insight, a leading provider of competitive intelligence and market analysis within the healthcare and lifesciences industry. With access data and analysis within the Biopharm Insight database, CHP has an enhanced capability to serve its client base. Through its affiliation with BioPharm Insight, CHP can arrange a complimentary demonstration of its capabilities. |
| Add to Outlook Calendar |
|
|
|
|
| arGentis™ announced that it has received a patent in Mexico for its flagship compound ARG201. ARG201 has been designated as an orphan drug for the treatment of Scleroderma. |
| Add to Outlook Calendar |
|
|
|
|
| Commercial Healthcare Partners (CHP) is pleased to announce that Molecular Design International (MDI) is a client. CHP will assist MDI in securing a partner for its novel technology to treat Diabetic Retinopathy. |
| Add to Outlook Calendar |
|
|
|
|
Based in Blue Bell, PA Stubbs & Hensel bridges the resource and experience gaps between Pharma/Biotech and Contract Research Organizations. Jim Usry, Principal of CHP says, “John Stubbs and Russ Hensel have extensive experience in managing projects for CROs and Pharma/Biotech companies and we are proud to be associated with Stubbs and Hensel Consulting. Their expertise adds to the value we bring potential partners.” |
| Add to Outlook Calendar |
|
|
|
|
| CHP has recently formed an alliance to assist companies interested in Business Development in Latin American markets. Contact us today for a free and confidential consultation. |
| Add to Outlook Calendar |
|
|
|
|
| Additionally, CHP has a number of clients wishing to in license late stage and marketed products in women’s health, urology, primary care, and oncology in the U.S. and Canadian markets. |
| Add to Outlook Calendar |
|
|
|
|
| Commercial Healthcare Partners (CHP) is currently seeking partnerships for organizations wishing to in license technologies for the treatment of Crohn’s disease, oncology, pain management, and wound care. Contact us today for a free and confidential consultation. |
| Add to Outlook Calendar |
|
|
|
|  |
|
---------------------------------------------- Commercial Healthcare Partners attended the Biotech Showcase partnering meeting associated with the JP Morgan healthcare conference held in San Francisco January 11-13, 2016. More than 30 meetings were held with potential partners as well as pharmaceutical and biotechnology companies. As a result of these meetings, the following opportunities were identified:
• Major pharmaceutical company looking to in-license products in all stages of development in the respiratory, autoimmune and allergy therapeutic areas
• Orphan drug company in Japan seeking to in-license late stage assets for Japanese markets. Current portfolio of products include dysmenorrhea, patent ductus arteriosus and Wilson’s disease
• Japanese pharma company is seeking products to replace the loss of its flagship product. Areas of interest include CNS, renal disease, behavioral medicine as well as a broad spectrum of additional pharma products
• Japanese company interested in in-licensing assets for the treatment of autoimmune diseases including arthritis, MS, hepatitis and other chronic diseases. Will consider early stage compounds.
• Marketing consultant with connections in the middle east will evaluate approved and late stage products for distribution in middle eastern markets.
• Chinese company interested in buying manufacturing facility in the U.S. Also interested in in-licensing products for the Chinese market including medical devices
• Well known Indian pharmaceutical manufacturer looking for ANDAs and 505(b)(2) assets for the U.S. market.
• Chinese pharma company desires to identify products for the Chinese and U.S. markets. Therapeutic areas of interest include oncology, Infectious Disease, auto-immune, neurology/pain management, diabetes, and metabolic disease
• U.S. based company offers Ex U.S. rights to CNS and GI products
• Chinese based consulting company looking to make an acquisition in the U.S.
• U.S. company interested looking to in-license products in the pain management space including opioid based products
• Large pharma company seeks products in the auto-immune space for the UK market
• Korean company seeks to in-license pharma products for the Korean market.
• Pharma company interested in in-licensing products for the treatment of gout, arthritic diseases, and pain management.
• Israeli company wants to add late stage assets in multiple therapeutic areas for the U.S. market. Will also consider an acquisition.
• Family owned pharma company wishes to identify assets that are designated as orphan drugs and are undergoing 505(b)(2) regulatory review. Will consider an acquisition.
To explore these opportunities, please contact us.
arGentis receives U.S Patent for Arthritis Treatment July 5, 2016--------
|
|
| |
|
| License in a Product? |
 |
| License out a Product? |
 |
| Find a Partner? |
|
| Find a Distributor? |
|
| Launch an Approved Product |
|
16 Jun 2017
-
CHP client signs an agreement to commercialize its 505(b)(2) asset for the treatment of Head and Neck Cancer
PNP Therapeutics:
BIRMINGHAM, Ala. - PNP Therapeutics Inc.
announced today the Food and Drug Administration has granted orphan drug status
to Gedeptin, the Company's lead product cand... View Release
11 May 2017
-
CHP client signs an agreement to commercialize its 505(b)(2) asset for the treatment of glaucoma.
"CHP client signs an agreement to commercialize its
505(b)(2) asset for the treatment of glaucoma.
The product is currently undergoing FDA review."
5 Jul 2016
-
arGentis receives U.S Patent for Arthritis Treatment
Memphis, TN—arGentis Pharmaceuticals, LLC announced today the issuance
of EU patent No. 2,286,218 for a single nucleotide polymorphism (SNP)
associated with resistance to immune tolerance. This... View Release
13 Jan 2016
-
CHP attended the Biotech Showcase partnering meeting
Commercial Healthcare Partners attended the Biotech Showcase partnering meeting associated with the JP Morgan healthcare conference held in San Francisco. More than 30 meetings were held with... View Release
25 Oct 2015
-
CHP collaboration with Finston Consulting
Commercial Healthcare Partners is pleased to announce a collaboration with Finston Consulting based in Washington, D.C. Finston Consulting will provide data room collection and management ser... View Release
27 Mar 2015
-
SynAllergy seeks sales representatives and contract sales organizations
SynAllergy seeks sales representatives and contract sales organizations to call on primary care physicians, pediatricians and other healthcare providers. Representatives receive a subst... View Release
6 Nov 2014
-
FDA Advisory Committee Recommends Rockwell Medical's Triferic for Iron Replacement and Maintenance of Hemoglobin in Hemodialysis Patients
WIXOM, Mich., Nov. 6, 2014 (GLOBE NEWSWIRE) -- Rockwell Medical, Inc. (RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD)... View Release
12 Aug 2014
-
Diabetic Retinopathy/Diabetic Macular Edema Compound
Established company with strong IP rights to early stage compound for the treatment of Diabetic Retinopathy/Diabetic Macular Edema wishes to discuss divestiture. Compound is supported by limi... View Release
11 Apr 2013
-
Rockwell Medical - SFP
What's happening NOW! Rockwell Medical Soluble
Ferric Pyrophosphate (SFP) Phase
III asset available from Rockwell Medicaland
24 Apr 2012
-
Novel therapy for the treatment of Alzheimer’s Disease and Parkinson’s Disease
Commercial Healthcare Partners is pleased to announce the availability of a novel therapy for the treatment of Alzheimer’s Disease and Parkinson’s Disease. This product is by product of nicot... View Release
4 Dec 2011
-
Head Lice Product available for in-licensing ex U.S.
Client company has product available for licensing in multiple countries outside the U.S. Product is not an insecticide and is available in the U.S. through a distribution partner that is wel... View Release
18 Apr 2011
-
Smoking Cessation
Company holds intellectual property rights to a unique combination of currently marketed products for smoking cessation. Company is interested in a partner to assist in further development an... View Release
15 Apr 2011
-
Locking Solution
A Unique locking solution being offered as an alternative to heparin. This technology is in the early stages of development. For more information, contact Commercial Healthcare Partners.
5 Mar 2011
-
Dry Eye Syndrome
Compound with unique transdermal delivery in Phase I development for the treatment of Dry Eye Syndrome. Company seeks development or licensing opportunity. Data presented to the America... View Release
2 Mar 2011
-
Product in Phase IIB
Compound available for licensing and/or development partnership. This product has been designated an orphan drug by the FDA for the treatment of Scleroderma. Additional patent is pendin... View Release
|
|
|
